Literature DB >> 24940767

Aberrant regulation of alternative pre-mRNA splicing in hepatocellular carcinoma.

Lijuan Liu1, Shuixiang Xie2, Chuanjie Zhang3, Fan Zhu4.   

Abstract

Alternative splicing of precursors messenger RNA (pre-mRNA) is commonly used to increase the diversity of messenger RNAs expressed by the genome in normal multicellular organisms. Dysregulation of alternative splicing underlies a number of human diseases, including cancers. Increasing evidence supports the important role of this expansive layer of gene regulation in hepatocarcinogenesis. Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide because of its aggressive property and limited therapeutic options. Studies suggest that aberrant alternative splicing promotes generation of oncogenic variants in HCC, whereas tumor suppressors are self-inactivated by aberrant alternative splicing in HCC. Moreover, different spliced variants of the same gene can display distinct and even antagonistic biological functions in HCC. As a result, inhibiting the splicing of oncogenic variants and the self-inactivation of tumor suppressors are likely to be new therapy strategies. This review provides a perspective of the emerging evidence of both alternative splicing as a critical mechanism for the development of HCC and that potential cross-talk through signaling pathways among different variants might aid in the development of novel molecular targets of HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24940767     DOI: 10.1615/critreveukaryotgeneexpr.2014007702

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  7 in total

1.  Elevated expression of ISY1, APOA-1, SYNE1, MTG1, and MMP10 at HCC initiation: HCC specific protein network involving interactions of key regulators of lipid metabolism, EGFR signaling, MAPK, and splicing pathways.

Authors:  Laila H Faraj Shaglouf; Maryam Ranjpour; Saima Wajid; Rakesh Tandon; Karisangal Ramaswamy Vasudevan; Swatantra Kumar Jain
Journal:  Protoplasma       Date:  2022-08-12       Impact factor: 3.186

2.  Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma.

Authors:  Lijuan Liu; Youyi Liu; Xiaobei Chen; Miao Wang; Yan Zhou; Ping Zhou; Wenxin Li; Fan Zhu
Journal:  Oncotarget       Date:  2017-07-04

3.  Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors.

Authors:  Young-Joo Jin; Seyoun Byun; Seonggyun Han; John Chamberlin; Dongwook Kim; Min Jung Kim; Younghee Lee
Journal:  BMC Med Genomics       Date:  2019-12-20       Impact factor: 3.063

Review 4.  Alternative RNA Splicing in Fatty Liver Disease.

Authors:  Panyisha Wu; Moya Zhang; Nicholas J G Webster
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-26       Impact factor: 5.555

5.  An Alternatively Spliced Variant of METTL3 Mediates Tumor Suppression in Hepatocellular Carcinoma.

Authors:  Rui-Yao Xu; Zhan Ding; Qing Zhao; Tiao-Ying Ke; Shu Chen; Xing-Yu Wang; Yao-Yun Wang; Meng-Fei Sheng; Wei Wang; Ni Long; Yu-Xian Shen; Yong-Zhen Xu; Wei Shao
Journal:  Genes (Basel)       Date:  2022-04-11       Impact factor: 4.141

Review 6.  Aberrant regulation of Wnt signaling in hepatocellular carcinoma.

Authors:  Li-Juan Liu; Shui-Xiang Xie; Ya-Tang Chen; Jing-Ling Xue; Chuan-Jie Zhang; Fan Zhu
Journal:  World J Gastroenterol       Date:  2016-09-07       Impact factor: 5.742

Review 7.  Aberrant expression of alternative isoforms of transcription factors in hepatocellular carcinoma.

Authors:  Olga Krivtsova; Anna Makarova; Natalia Lazarevich
Journal:  World J Hepatol       Date:  2018-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.